Clinical Trials Logo

Advanced Prostate Cancer clinical trials

View clinical trials related to Advanced Prostate Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05590793 Active, not recruiting - Clinical trials for Metastatic Prostate Cancer

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

Start date: November 17, 2022
Phase: Phase 3
Study type: Interventional

The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate. Participants will receive 1 injection of triptorelin pamoate 6-month formulation.

NCT ID: NCT04117594 Active, not recruiting - Clinical trials for Advanced Prostate Cancer

Whole Body Magnetic Resonance Imaging Study

WISE
Start date: October 9, 2019
Phase:
Study type: Observational

In prostate cancer bone is the most common site for cancer spread, causing pain, fractures, nerve compression and death. New therapies are available for treating bone disease from cancer and this means that by maintaining patients on drugs that are effective and switching patients to other drugs when current treatment becomes ineffective, patients can be maintained 'better for longer'. However, to do this, it is necessary to accurately tell whether a given treatment is working or not. In this study, the investigators will perform whole body MRI scans, which include a special scan called diffusion-weighted MRI (DWI MRI) that can provide more information about the participants extent of disease. The investigators aim to show that this test is better than the standard tests of CT and bone scan currently used in the NHS to monitor bone disease. The information from this study will be used to test a special software so that the test may more widely benefit patients across the NHS in the future.

NCT ID: NCT03511196 Active, not recruiting - Prostate Cancer Clinical Trials

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Start date: September 17, 2018
Phase: Early Phase 1
Study type: Interventional

Adaptive Androgen Deprivation Therapy (ADT) plus Standard of Care. The purpose of this study is to develop adaptive therapy for high risk metastatic castration sensitive prostate cancer (mCSPC).

NCT ID: NCT02925702 Active, not recruiting - Clinical trials for Advanced Prostate Cancer

PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.

PRORADIUM
Start date: February 2016
Phase:
Study type: Observational

PRORADIUM is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with radium-223.

NCT ID: NCT02922218 Active, not recruiting - Clinical trials for Advanced Prostate Cancer

PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.

PROSENZA
Start date: June 2016
Phase:
Study type: Observational

PROSENZA is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with enzalutamide

NCT ID: NCT02787837 Active, not recruiting - Clinical trials for Advanced Prostate Cancer

PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.

PROSABI
Start date: May 2014
Phase:
Study type: Observational

PROSABI is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with abiraterone

NCT ID: NCT02420977 Active, not recruiting - Clinical trials for Advanced Prostate Cancer

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

Start date: December 6, 2018
Phase: Early Phase 1
Study type: Interventional

This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.

NCT ID: NCT02362620 Active, not recruiting - Clinical trials for Advanced Prostate Cancer

PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.

PROSTAC
Start date: May 2014
Phase:
Study type: Observational

PROSTAC is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with docetaxel or cabazitaxel

NCT ID: NCT01224405 Active, not recruiting - Clinical trials for Advanced Prostate Cancer

Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy

PON-PC-02
Start date: April 2010
Phase: Phase 3
Study type: Interventional

The study includes the recruitment of patients with advanced prostate cancer resistant to chemical castration This is a multicenter prospective trial randomized phase III